Trial Profile
Phase II Randomized Study Of Neoadjuvant And Adjuvant Abiraterone Acetate + Apalutamide For Intermediate-High Risk Prostate Cancer Undergoing Prostatectomy
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 11 Mar 2024
Price :
$35
*
At a glance
- Drugs Abiraterone acetate (Primary) ; Apalutamide (Primary) ; Leuprorelin; Prednisone
- Indications Adenocarcinoma; Prostate cancer
- Focus Therapeutic Use
- 27 Jan 2024 Results from part 2, presented at the 2024 Genitourinary Cancers Symposium
- 01 Jan 2024 Results part 2 of a randomized phase 2 trial published in the Cancer
- 24 Jul 2023 Planned primary completion date changed from 1 Jun 2023 to 1 Sep 2023.